retatrutide type 2 diabetes trial results Retatrutide, a GIP, GLP-1 and glucagon receptor agonist, for people with diabetes: a randomised, double-blind, placebo and active-controlled, parallel-group, phase 2 conducted in the USA Eli Lilly just announced striking

A study by Mass Eye and Ear (which was published in JAMA Ophthalmology) found that those on semaglutide were four times more likely to develop NAION (17 of 200 diabetes patients) and seven times more likely to develop NAION if they were also obese or overweight (20 of 361 overweight or obese patients)

This triple-pathway activation addresses blood glucose regulation, appetite suppression, AND increased energy expenditure at the same time

Oral magnesium supplementation for insomnia in older adults: A systematic review and meta-analysis.BMC Complementary Medicine and Therapies, 21 (1), 125

Reapply sunscreen at least every two hours, or after 40 minutes if youre swimming or sweating

Let iFIT Trainer John Peel guide you step-by-step with low-impact, form-focused movements designed to protect your hard-earned muscle.Start Training with John Peel on the iFIT Workout App